New therapy, new hope for aggressive breast cancer patients

By Jodi Mohrmann, Managing editor of special projects, jmohrmann@wjxt.com
Published On: Jan 16 2014 06:47:17 AM EST
Updated On: Jan 16 2014 07:40:00 AM EST
SEATTLE, Wash. -

Triple negative breast cancer accounts for about 15 percent of all new breast cancer cases in the U.S., but it leads to 25 percent of all breast cancer deaths. A diagnosis of triple negative breast cancer means that the three most common types of receptors known to fuel most breast cancer growth are not present in the cancer tumor. It’s an aggressive cancer that—until now—has only been treated with standard chemo. Now, a new therapy is offering patients hope for the first time.

Eight years ago, Brenda Beguin was diagnosed with an aggressive breast cancer. Three years ago, it came back.

“My doctor actually told my daughter and I, ‘Instead of doing chemotherapy, you probably should just do the most that you can with the life that you have,’” Beguin said.

However, Beguin didn’t listen. She enrolled in a clinical trial testing new therapies for triple negative cancer.

“Right now, the only treatment we have for triple negative breast cancer is chemotherapy,” explained Julie R. Gralow, MD, Director, Breast Medical Oncology at Seattle Cancer Care Alliance.

Doctors are now studying PARP inhibitors to prevent cancer cells from becoming resistant to chemo.

“It affects the ability of the tumor cell to heal itself after getting chemotherapy,” Gralow said.

One other study found triple negative patients with advanced cancer who took the drugs with chemo survived about five months longer than those who received chemo only, with very few side effects. 

Today, Beguin only takes the PARP drug.

“I feel it has saved my life,” she said.

Gralow says one downside of the PARP inhibitors is they are very expensive. While still in clinical trials, she estimates they might cost between 2,000 and 10,000 dollars a month, if they hit the market.

The next step for this research is a larger clinical trial that will test the drug on more patients. During the clinical trial, patients get the drug for free.

Additional Information:

About 10 to 20 percent of breast cancers—more than one out of every 10—are found to be triple negative.   Triple negative breast cancer (TNBC) is a cancer that tests negative for estrogen receptors, HER2, and progesterone receptors. If a woman is to test negative for all three factors, than she has triple-negative breast cancer, meaning that the patient will not respond to hormonal therapy or treatments that target HER2 receptors. Triple negative breast cancer is more often seen in African American women, Hispanic/Latina women, and younger women. Triple negative breast cancer is also more aggressive than most cancers and it is less likely to be seen on a mammogram. This cancer is known to be reoccurring and it is more likely to spread to other parts of the body. (Source: breastcancer.org/symptoms/diagnosis/trip_neg and http://ww5.komen.org/uploadedFiles/Content_Binaries/KOMEED079100.pdf)

TREATMENT: TNBC is treated with a combination of surgery, radiation, and chemotherapy.  Since it tests negative for the three receptors, it isn’t treated with hormone or targeted therapy. If the cancer is caught early enough, it can be treated. Chemotherapy works well in TNBC.  It may work even better for TNBC than for other types of breast cancer.  (Source: www5.komen.org/uploadedFiles/Content_Binaries/KOMEED079100.pdf)

NEW THERAPY: PARP inhibitors, also known as poly ADP-ribose polymerase, are now being studied to treat patients with triple negative breast cancer. One study in 2011 found that the PARP inhibitor boosted overall survival to a median 12.3 months compared with 7.7 months with chemotherapy alone, according to Joyce O’Shaughnessy, MD, of Baylor Sammons Cancer Center in Dallas.  Patients on the drug showed similar gains in objective response, clinical benefit, and progression-free survival, with no significant difference in adverse events in the open-label phase II trial.  Normal cells favor a BRCA ½-dependant process to repair double-strand breaks in DNA, which are caused by radiation and some chemotherapy.  Although patients with BRAC1 or BRCA2 mutations have one functional allele that keeps this mechanism in play for normal cells, cancer cells usually inactivate that allele (allele is one or two more versions of a gene). PARP inhibitors exploit that vulnerability by keeping double-strand breaks from being repaired in cells without the BRCA repair function.  Triple negative tumors share characteristics with BRCA1 breast tumors and may have other genetic lesions that impair double-strand repair. However, researchers say to use caution.  This trial included only 123 patients with metastatic breast cancer negative for estrogen receptor (ER), progesterone receptor (PR), and HER2 overexpression, which is a small cohort.  (Source:medpagetoday.com/HematologyOncology/BreastCancer/24195)

Comments

The views expressed below are not those of News4Jax or its affiliated companies. By clicking on "Post," you acknowledge that you have read the Terms of Service and your comment is in compliance with such terms. Readers, please help keep this discussion respectful and on topic by flagging comments that are offensive or inappropriate (hover over the commenter's name and you'll see the flag option appear on right side of that line). And remember, respect goes both ways: Tolerance of others' opinions is important in a free discourse. If you're easily offended by strong opinions, you might skip reading comments entirely.

blog comments powered by Disqus